New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export SCTX’s income statement to Excel — free account
Scribe Therapeutics Inc.
SCTXScribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.
12.07
1.15
−8.70%
After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.
Follow SCTX
Alert me
Scribe Therapeutics Inc. (SCTX) valuation and DCF model
Scribe Therapeutics Inc. is not valued here: no trailing free cash flow or shares to value.
Valuation against its own history
| Multiple | Current | 5Y avg | 10Y avg | vs 10Y avg | Industry median | vs industry | 10Y range |
|---|---|---|---|---|---|---|---|
| P/B | 1.40× | 1.40× | 1.40× | 0% above | 2.04× | 32% below | |
| EV/Sales | 0.02× | 0.19× | 0.19× | 90% below | 8.00× | 100% below |
SCTX trades at 1.40× P/B, against a 10-year average of 1.40× (range 1.40×–1.40×). Re-rating to the average implies $12.07 per share.